Johnson & Johnson (JNJ) Other Working Capital Changes (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Other Working Capital Changes came in at -$349.0 million in Q1 2026, down 126.5% year-on-year from $1.3 billion in Q1 2025, and up 76.51% quarter-over-quarter from -$1.5 billion in Q4 2025.

Johnson & Johnson (JNJ) Other Working Capital Changes (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Other Working Capital Changes across 18 years of filings, most recently posting -$349.0 million for Q1 2026.

  • Other Working Capital Changes for Q1 2026 came in at -$349.0 million, down 126.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (up 60.81% YoY), and the FY2025 annual result was $6.2 billion, up 459.17% from the prior year.
  • Other Working Capital Changes came in at -$349.0 million for Q1 2026 at Johnson & Johnson, up from -$1.5 billion in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $4.9 billion in Q2 2025 to a low of -$3.2 billion in Q1 2024.
  • The 5-year median for Other Working Capital Changes is $229.0 million (2023), against an average of $532.1 million.
  • Peak annual rise in Other Working Capital Changes reached 1153.15% in 2024, while the deepest fall reached 449.62% in 2024.
  • Johnson & Johnson's Other Working Capital Changes stood at -$995.0 million in 2022, then soared by 312.46% to $2.1 billion in 2023, then plunged by 136.33% to -$768.0 million in 2024, then tumbled by 93.49% to -$1.5 billion in 2025, then surged by 76.51% to -$349.0 million in 2026.
  • The last three Other Working Capital Changes figures came in at -$349.0 million (Q1 2026), -$1.5 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 29, 2026 -349.00 Mn
Mar 29, 2026 -349.00 Mn
Dec 28, 2025 -1.49 Bn
Dec 28, 2025 -1.49 Bn
Sep 28, 2025 1.46 Bn
Sep 28, 2025 1.46 Bn
Jun 29, 2025 4.88 Bn
Jun 29, 2025 4.88 Bn
Mar 30, 2025 1.32 Bn
Mar 30, 2025 1.32 Bn
Dec 29, 2024 -768.00 Mn
Dec 29, 2024 -768.00 Mn
Sep 29, 2024 2.78 Bn
Sep 29, 2024 2.78 Bn
Jun 30, 2024 -532.00 Mn
Jun 30, 2024 -532.00 Mn
Mar 31, 2024 -3.20 Bn
Mar 31, 2024 -3.20 Bn
Dec 31, 2023 2.11 Bn
Dec 31, 2023 2.11 Bn